Abstract
Proton pump inhibitors (PPI) remains important therapeutic option for esophagitis and gastritis. However recent studies demonstrate no benfit when prescribing PPIs for chronic cough, infantile reflux, asthma, or functional gastrointestinal disorders.
Recent studies suggest averse effects on microbiome diversity and immune function, resulting in increased rate of gastrointestinal infections, bone fractures and atopic disorders.